{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not estimable due to censoring.","groupId":"OG000","lowerLimit":"24.48","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"TTNT was defined as the time from the date of first dose of study drug to the date of the first dose of next-line of antineoplastic therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Efficacy Population included all participants who received ixazomib treatment for the duration of their study participation. As prespecified in the SAP, the Efficacy Population contained only one arm i.e., Ixazomib (efficacy outcomes data for the participants who received placebo before Protocol Amendment 8 was not collected per SAP), thus data is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Up to 58.4 months","title":"Time to Next-Line Therapy (TTNT)","type":"SECONDARY","unitOfMeasure":"months"}